Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Invested Capital (2020 - 2025)

Historic Invested Capital for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $607.7 million.

  • Relay Therapeutics' Invested Capital fell 2755.55% to $607.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.7 million, marking a year-over-year decrease of 2755.55%. This contributed to the annual value of $777.8 million for FY2024, which is 342.94% up from last year.
  • Latest data reveals that Relay Therapeutics reported Invested Capital of $607.7 million as of Q3 2025, which was down 2755.55% from $665.7 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Invested Capital peaked at $999.8 million during Q3 2022, and registered a low of $571.1 million during Q3 2021.
  • Its 5-year average for Invested Capital is $771.3 million, with a median of $777.8 million in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 46213.61% in 2021, then crashed by 2755.55% in 2025.
  • Relay Therapeutics' Invested Capital (Quarter) stood at $897.8 million in 2021, then rose by 5.84% to $950.2 million in 2022, then decreased by 20.86% to $752.0 million in 2023, then grew by 3.43% to $777.8 million in 2024, then dropped by 21.87% to $607.7 million in 2025.
  • Its Invested Capital was $607.7 million in Q3 2025, compared to $665.7 million in Q2 2025 and $721.1 million in Q1 2025.